nach oben

Arthritis Research & Therapy

Erschienen in:

01.12.2007 | Editorial

Is interleukin-1 a good target for therapeutic intervention in intervertebral disc degeneration: lessons from the osteoarthritic experience

verfasst von: Philippe Goupille, Denis Mulleman, Xavier Chevalier

Erschienen in: Arthritis Research & Therapy | Ausgabe 6/2007

Einloggen, um Zugang zu erhalten

Abstract

IL-1 plays a key role in disc degeneration and could be a valid target for inhibiting this process. IL-1 receptor antagonist (IL-1ra) might be a good candidate to inhibit IL-1 activity. However, many questions need to be addressed before contemplating therapy in humans. IL-1 blockade is also a great challenge in osteoarthritis and results from animal models suggest that IL-1ra may have beneficial effects. The clinical benefit of a local injection of IL-1ra in knee osteoarthritis may be limited by the antagonist's short half-life. Further studies with longer-lasting antagonists are needed to explore this new therapeutic approach.

Le Maitre CL, Hoyland JA, Freemont AJ: Catabolic cytokine expression in degenerate and herniated human intervertebral discs: IL-1β and TNFα expression profile. Arthritis Res Ther. 2007, 9: R77-10.1186/ar2275.PubMedCentralCrossRefPubMed

Le Maitre CL, Hoyland JA, Freemont AJ: Interleukin-1 receptor antagonist delivered directly and by gene therapy inhibits matrix degradation in the intact degenerate human intervertebral disc: an in situ-zymographic and gene therapy study. Arthritis Res Ther. 2007, 9: R83-10.1186/ar2282.PubMedCentralCrossRefPubMed

Le Maitre CL, Hoyland JA, Freemont AJ: The role of interleukin-1 in the pathogenesis of human intervertebral disc degeneration. Arthritis Res Ther. 2005, 7: R732-R745. 10.1186/ar1732.PubMedCentralCrossRefPubMed

Le Maitre CL, Hoyland JA, Freemont AJ: A preliminary in vitro study into the use of IL-1Ra gene therapy for the inhibition of intervertebral disc degeneration. Int J Exp Pathol. 2006, 87: 17-28. 10.1111/j.0959-9673.2006.00449.x.PubMedCentralCrossRefPubMed

Caron JP, Fernandes JC, Martel-Pelletier J, Tardif G, Mineau F, Geng C, Pelletier JP: Chondroprotective effect of intra-articular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum. 1996, 39: 1535-1544. 10.1002/art.1780390914.CrossRefPubMed

Pelletier JP, Caron JP, Evans C, Robbins PD, Georgescu HI, Jovanovic D, Fernandes JC, Martel-Pelletier J: In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum. 1997, 40: 1012-1019. 10.1002/art.1780400604.CrossRefPubMed

Fernandes JC, Tardif G, Martel-Pelletier J, Lascau-Coman V, Dupuis M, Moldovan F, Sheppard M, Krishnan BR, Pelletier JP: In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol. 1999, 154: 1159-1169.PubMedCentralCrossRefPubMed

Chevalier X, Giraudeau B, Conrozier T, Marlière J, Kiefer P, Goupille P: Safety study of intraarticular injection of interleukin 1 receptor antagonist: a multicenter study. J Rheumatol. 2005, 32: 1317-1323.PubMed

Chevalier X, Goupille P, Beaulieu AD, Burch FX, Conrozier T, Loeuille D, Kivitz AJ, Silver D, Kiefer P, Zhou L, et al: Results from a double blind, placebo-controlled, multicenter trial of a single intra-articular injection of Anakinra (Kineret^®) in patients with osteoarthritis of the knee. Arthritis Rheum. 2005, 52 (Suppl 9): S507-

Titel: Is interleukin-1 a good target for therapeutic intervention in intervertebral disc degeneration: lessons from the osteoarthritic experience
verfasst von: Philippe Goupille
Denis Mulleman
Xavier Chevalier
Publikationsdatum: 01.12.2007
Verlag: BioMed Central
Erschienen in: Arthritis Research & Therapy / Ausgabe 6/2007
Elektronische ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar2324

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Is interleukin-1 a good target for therapeutic intervention in intervertebral disc degeneration: lessons from the osteoarthritic experience

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2007

A critical appraisal of guidelines for the management of knee osteoarthritis using Appraisal of Guidelines Research and Evaluation criteria

Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation

Activation of proteinase-activated receptor 2 in human osteoarthritic cartilage upregulates catabolic and proinflammatory pathways capable of inducing cartilage degradation: a basic science study

Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial

Inorganic pyrophosphate generation by transforming growth factor-beta-1 is mainly dependent on ANK induction by Ras/Raf-1/extracellular signal-regulated kinase pathways in chondrocytes

Cyclooxygenase inhibition lowers prostaglandin E2 release from articular cartilage and reduces apoptosis but not proteoglycan degradation following an impact load in vitro

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin